SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (768)5/10/1999 9:46:00 PM
From: LLCF  Read Replies (1) of 1386
 
<At this point, the cash on hand doesn't seem enough to go very far without another infusion unless a money infusing deal is made fairly soon for HU 211. This seems unlikely in the face of the current and persistent amount of short selling. Fortunately, they did structure a reasonable financial arrangement so no serious disruption seems around the bend.>

Not to be arguementative, but what does the short selling have to do with a deal with HU 211? Then you're saying they need an infusion, but already have it set up?

On a brighter note, IMO the earnings couldn't have looked much better, and I'm starting to think this one might actually be a big winner! Why?

1.) I love the low market share that the Lotemax(5.2%) & Alrex(6.6%) sales represent. With BOL behind the marketing (vs Pars) there is no reason these sales %'s can't go up 5X or more. This would cover current burn and stabilize the company.

2.) "March sales, while also affected by seasonal patterns, were nearly three times larger than those in January."

3.)"development of our third ophthalmic product remains on schedule for an NDA filing this year and a product launch in 2000"

4.) I think it's clear now that PARS will be able to "scrape by" (even if it means delaying research) which gives them nice leverage in their HU 211 partnering effort.

DAK
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext